Breast
cancer generally occurs when breast cells grow uncontrollably. Mostly,
breast cancer development starts in the duct that carries milk to the nipples.
Some breast cancer cells develop in milk producing glands. As per the National
Institutes of Health (NIH), in the U.S., 14.6% of all new cancer cases
diagnosed every year are of breast cancer.
Also, as per the American Cancer Society (ACS), 1 in every 5
woman has cancer cell in their breast tumour with several growth promoting
protein receptors on their surface. HER2 (human epidermal growth factor
receptor 2) gene plays significant role in the development of breast cancer in
most of the cases. Alpelisib is one of the key pipeline drug candidates for
hormone sensitive breast cancer pipeline. Pfizer Inc., and Novartis AG are
major players involved in the development of drugs for hormone sensitive breast
cancer.
Request to Get the Sample Pages at:
The report provides a comprehensive understanding of the
pipeline activities covering all drug candidates under various stages of
development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product
description and development activities including information about clinical
results, designations, collaborations, licensing, grants, technology, and
others.
No comments:
Post a Comment